GPOs May Spurn Anti-Competitive Contracts After Masimo v. Tyco – MDMA

Masimo believes its $420 mil. legal victory over Tyco will spur large manufacturers and GPOs to gradually alter their business practices, resulting in long-term cost savings for hospitals

More from Archive

More from Medtech Insight